Arrowhead Pharmaceuticals Insider Matthew Cohen Buys 11,882 Shares on New RSU Grant After Board Appointment—Signal of Confidence in Gene‑Silencing Platform?
Arrowhead insiders signal confidence: Matthew Cohen’s new RSU grant shows faith in the gene‑silencing platform, hinting at potential upside as clinical milestones loom.
- ARROWHEAD PHARMACEUTICALS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read